Skip to main content
TipRanks
Go Ultimate75% OFF

Zimmer Biomet Holdings (ZBH) AI Stock Analysis

1,109 Followers
ZBH

Zimmer Biomet Holdings

(NYSE:ZBH)

Select Model
Rating:69Neutral
Price Target:$121.00â–²(18.52% Upside)
Action:reiterated
Date:11/05/26

ZBH scores positively on fundamentals and the latest earnings update: revenue growth, durable cash generation, and raised 2026 guidance with significant buybacks support the outlook. The technical picture is strong but overbought, which raises near-term volatility risk. The main drag on the score is valuation (higher P/E with a low dividend yield) alongside ongoing margin pressure, knee franchise weakness, and China headwinds.

Positive Factors
Revenue Growth and Portfolio BreadthZimmer Biomet combines a multi-year upward revenue trajectory with broad momentum across hips, S.E.T., technology and data. This diversification reduces reliance on one product line, supports recurring procedure-driven demand, and gives the company multiple avenues to sustain growth over the next several quarters.
Negative Factors
Knee Franchise WeaknessThe knee franchise remains a meaningful area of weakness, with declines in both U.S. and international markets and management expecting continued near-term pressure. Persistent underperformance could dilute growth from stronger hip and technology categories and indicates unresolved commercial execution challenges.

Zimmer Biomet Holdings Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.

$0.00$500.00M$1.00B$1.50B$2.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

U.S. sales are clearly the growth engine—steadier and accelerating into 2026—while international revenues are more volatile and still grappling with China and emerging‑market weakness. Management’s raised guidance and strong U.S. organic growth reflect hip, robotics, and Paragon contributions (Paragon adds ~110bps), but international recovery is uneven and supply constraints/price pressure could limit upside. For investors, the story is U.S.-led marginable growth and cash-funded buybacks, with international execution and pricing erosion the main near‑term risks to sustain momentum.

Data provided by:The Fly

Zimmer Biomet Holdings (ZBH) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%25%ZBH+15.85%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$19.32B
Dividend Yield
0.94%
Average Volume (3M)
2.10M
Price to Earnings (P/E)
25.9
Beta (1Y)
0.29
Revenue Growth
6.98%
EPS Growth
-2.22%
Country
US
Employees
17,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Zimmer Biomet Holdings Business Overview & Revenue Model

Company Description

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products...

How the Company Makes Money

Zimmer Biomet makes money primarily by selling orthopedic implants, surgical instruments, and related enabling technologies to healthcare providers, with revenue recognized from product sales through a combination of direct sales forces and distribut...

Zimmer Biomet Holdings Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:5.18%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was broadly positive. Zimmer Biomet reported solid third-quarter growth, strong performance across Hips, S.E.T. and technology, significant cash generation, progress in its commercial transformation and multiple increases to its 2026 outlook. The main challenges were declining knee sales, China-related headwinds, margin pressure from manufacturing costs and ongoing investment in the U.S. sales force. Management expressed confidence in the long-term strategy and expects improved knee performance and additional growth catalysts in 2027.

Positive Updates

Solid Third-Quarter Revenue Growth
Third-quarter total net sales were $2.63 billion, representing 3.1% reported growth and 3.7% constant currency growth versus the third quarter of 2025. Excluding the negative impact of the China distributor network consolidation strategy, constant currency growth would have been 4.7%.

Negative Updates

Knee Business Decline
Global Knee sales declined 2.6% on a constant currency basis, including a 2% decrease in the U.S. and a 3.4% decrease internationally. Management expects continued near-term pressure in the knee business.

Company Guidance

Zimmer Biomet raised its 2026 organic constant currency sales growth guidance to a range of 3% to 3.5% from 2.25% to 3.25%, adjusted earnings per share guidance to $8.50 to $8.60 from $8.47 to $8.59, and reported sales growth guidance to 4.4% to 4.9% from 3.9% to 4.9%; foreign exchange is expected to be an approximate 25 basis point tailwind, Paragon 28 to contribute 110 basis points, China-related headwinds to total nearly 100 basis points in the fourth quarter and roughly 50 basis points for the full year 2026, adjusted gross margin to be around 72%, adjusted operating margin to decline a little more than 50 basis points year-over-year, net interest and other nonoperating expenses to be $300 million, the adjusted tax rate approximately 18%, share repurchases approximately $1 billion, fully diluted weighted average shares around 193 million, and free cash flow to grow 9% to 11%; pricing is expected to be flat to 100 basis points of pressure, the company aspires to a 6% WAMGR by the end of the decade, expects 2027 to be a better year compared to 2026, and anticipates Monogram can launch in the first half of 2027, pending approval.

Zimmer Biomet Holdings Financial Statement Overview

Summary

Solid business quality with rising revenue and generally healthy profitability, supported by durable free cash flow that exceeds net income in the TTM. Offsets include margin compression versus 2023–2024 highs, choppy free cash flow growth, and moderately higher leverage versus prior years.

Income Statement

72Positive

Balance Sheet

68Positive

Cash Flow

63Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.57B8.23B7.68B7.39B6.94B6.83B
Gross Profit5.97B5.07B5.49B5.31B4.92B4.87B
EBITDA2.29B2.22B2.25B2.22B1.49B1.65B
Net Income767.50M705.20M903.80M1.02B231.40M401.60M
Balance Sheet
Total Assets23.54B23.09B21.37B21.50B21.07B23.46B
Cash, Cash Equivalents and Short-Term Investments399.90M591.90M525.50M415.80M375.70M378.10M
Total Debt7.50B7.52B6.20B5.77B5.70B7.07B
Total Liabilities10.81B10.39B8.89B9.01B9.04B10.79B
Stockholders Equity12.73B12.70B12.47B12.48B12.02B12.66B
Cash Flow
Free Cash Flow1.66B1.47B1.14B1.19B1.07B1.35B
Operating Cash Flow1.88B1.70B1.50B1.58B1.28B1.50B
Investing Cash Flow-1.22B-1.98B-888.10M-778.90M-529.20M-503.60M
Financing Cash Flow-1.56B326.00M-484.50M-763.50M-843.80M-1.31B

Zimmer Biomet Holdings Technical Analysis

Technical Analysis SentimentPositive
Last Price102.09

Price Trends

50DMA95.92Positive
100DMA95.31Positive
200DMA92.31Positive

Market Momentum

MACD2.54Positive
RSI53.60Neutral
STOCH25.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZBH, the sentiment is Positive. The current price of 102.09 is above the 20-day moving average (MA) of 101.27, above the 50-day MA of 95.92, and above the 200-day MA of 92.31, indicating a bullish trend. The MACD of 2.54 indicates Positive momentum. The RSI at 53.60 is Neutral, neither overbought nor oversold. The STOCH value of 25.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZBH.

Zimmer Biomet Holdings Risk Analysis

Zimmer Biomet Holdings disclosed 32 risk factors in its most recent earnings report. Zimmer Biomet Holdings reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our product portfolio rationalization activities may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our portfolio rationalization initiatives.Q4, 2025
2.Our commitments, goals and disclosures related to corporate responsibility matters, and the perception of our activities in these areas, may adversely impact us.Q4, 2025
3.We are transforming aspects of our sales and distribution network and go-to-market model in the U.S. and certain other markets, and these efforts may not be successful and they involve risks and challenges that may adversely impact our business, results of operations and financial condition.Q4, 2025

Zimmer Biomet Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ZBH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$130.88B25.1310.60%2.80%9.77%12.28%
SYKSYK75Outperform$120.88B33.6115.61%1.11%7.87%22.82%
GMEDGMED73Outperform$9.27B16.9911.82%―13.35%32.22%
SNNSNN69Neutral$12.72B20.0212.25%2.60%5.26%31.02%
ZBHZBH69Neutral$19.32B25.926.05%0.94%6.98%-2.22%
BVSBVS66Neutral$893.17M12.4227.23%―3.87%623.68%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%ZBHMDTSNNSYKGMEDBVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ZBH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ZBHZimmer Biomet Holdings102.0913.5915.35%
MDTMedtronic102.325.205.35%
SNNSmith & Nephew Snats30.51-0.95-3.01%
SYKStryker Corp317.54-42.70-11.85%
GMEDGlobus Medical69.99-13.83-16.50%
BVSBioventus, Inc.10.603.8857.74%

Zimmer Biomet Holdings Corporate Events

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

Zimmer Biomet Restructures Leadership to Boost U.S. Growth

Positive
Sep 8, 2026

On September 8, 2026, Zimmer Biomet announced a restructuring of its Americas and Global Business Group leadership, promoting Gary Campbell to President, Americas, Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery, and Bradley Kes...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026